Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Phase 4

Terminated

• Conditions: Central Retinal Vein Occlusion; Macular Edema

• Registration Number: NCT00566761
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Detailed Description

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Study Timeline

• Study Start: 2007-06
• Primary Completion: 2007-06
• Study First Submitted: 2007-11-30
• Study First Submitted QC: 2007-11-30
• Study First Posted: 2007-12-04
• Study Completion: 2008-03
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Macular edema secondary to central retinal vein occlusion
• BCVA worse than 20/40
• Central macular >250 mc with OCT

Exclusion Criteria

• Diabetic retinopathy or other retinopathy
• Media opacity that does not allow following
• steroid responder
• diagnosed glaucoma or IOP > 21 mmHg

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Changes in Best corrected visual acuity and macular edema measured with OCT	Follow up to 3 , 6 and 12 months

Secondary Outcome Measures

Name	Time	Method
Report treatment complications	12 month

Trial Locations

Locations (1)

Asociacion Para Evitar la Ceguera en Mexico; 🇲🇽 Mexico city, Coyoacan, Mexico